Iodine-131 is by far the most important radionuclide released from the Idaho Chemical Processing Plant, and it was included in a detailed analysis of doses to members of the public. A more refined analysis was also performed for the other 12 radionuclides released from ICPP (Sr-89; Sr-90; Y-91; Zr-95; Nb-95; Ru-103; I-133; Ba-140; Ce-141; Ce-144; Pr-143; and Pu-238).

Estimated I-131 thyroid doses from ICPP were typically less than 4 cSv for individuals who lived at the closest locations downwind from ICPP. Thyroid doses were almost always less than 20 cSv to thyroid. More than 90% the people living around INEL received thyroid doses of less than 0.4 cSv to the thyroid.

Iodine-131 doses from ICPP are lower than doses from other nuclear operations (e.g., Hanford, Washington, or Oak Ridge, Tennessee) and also lower than doses from I-131 fallout from nuclear weapons testing at Nevada Test Site.

Other radionuclides released from ICPP produced effective doses of less than 0.1 cSv, or organ doses of less than 1 cSv. The dose to an individual from all radionuclides combined at the closest downwind location is equivalent to a thyroid dose of 2 cSv from ingestion of I-131.

Dose Assessment Report

Principal authors:
A. Iulian Apostoaei, Oak Ridge Center for Risk Analysis, Inc.
Brian A. Thomas, Oak Ridge Center for Risk Analysis, Inc.
David C. Kocher, Oak Ridge Center for Risk Analysis, Inc.
F. Owen Hoffman, Oak Ridge Center for Risk Analysis, Inc.

INEL Dose Reconstruction 
​Doses and projected health effects to the Public